A Prospective Audit On The Management Of Ocular Surface Disease Involving Inflammation With A Sutureless Human Amniotic Membrane Dehydrated Matrix Using A Digital Ocular Surface Disease Assessment Tool
Published 2023 - 41st Congress of the ESCRS
Reference: FP22.05 | Type: Free paper | DOI: 10.82333/xr65-xc26
Authors: Mohamed Elalfy* 1 , Sundas Maqsood 2
1Corneo plastic unit,Queen Victoria Hospital,East Grinstaed,United Kingdom;Ophthalmology,Maidstone and Tunbridge Wells Hospitals,Maidstone,United Kingdom;Cornea,Research institute of Ophthalmology,Giza,Egypt, 2Corneo plastic unit,Queen Victoria Hospital,East Grinstaed,United Kingdom;Ophthalmology,Maidstone and Tunbridge Wells Hospitals,Maidstone,United Kingdom
Purpose
To report the outcomes of using a sutureless human amniotic membrane dehydrated matrix (HAMDM) in the management of a range of ocular surface conditions.
Setting
Prospective
Methods
In a prospective audit across two UK NHS centres; Queen Victoria Hospital Foundation Trust, East Grinstead, and Maidstone and Tunbridge Wells Trust, Kent, 46 eyes of 46 patients (25 male, 21 female) were treated with sutureless HAMDM in a patient cohort with an age range of 9-94 years. The audits main outcome was resolution of the epithelial defect, resolution of inflammation at the ocular surface and best-corrected visual acuity. Measurements were taken using AOS digital imaging software to assess ocular surface inflammation by blood vessel imaging and measure epithelial defect size (mm2).
Results
A total of 47 applications of sutureless HAMDM on 46 eyes of 46 patients were assessed across a various aetiology. Patients were treated for an average of 24.0 ±14.1 days. These included: limbal stem cell deficiency (n=17), persistent epithelial defects (n=16), neurotrophic cornea (n=7),. Across the patent cohort, 63% of eyes showed complete healing, with an additional 32.6% of eyes showing partial resolution. The average rate of healing (wound closure) was 0.36 mm2 per day across the patient cohort, with completely resolved patients experience a rate 0.41mm2 per day. I Visual acuity across the patient cohort was generally stable (61%) and improved in 26% of patients (0.06 ± 0.51 LogMAR).
Conclusions
Sutureless HAMDM can effectively treat a range of ophthalmic patient cohorts in a clinical, non-surgical setting using a simple 4 to 6-minute sutureless contact lens application procedure. The AOS imaging software offered a quantitative methodology for measuring epithelial defect size and inflammation state, however, improving the accuracy and automation of the technology will improve its ability to be integrated as a tool in the healthcare system